FDA
-
-
-
-
-
-
-
TD Cowen on Verrica Pharmaceuticals (VRCA): 'We are encouraged by the increased Ycanth prescribing in lieu of compounded cantharidin'
-
-
-
-
-
-
-
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
-
-
-
-
-
-
-
Verrica Pharmaceuticals (VRCA) Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment
-
-
-
-
-
-
-
Verrica Pharmaceuticals Inc. (VRCA) named Gavin Corcoran MD to board
-
-
-
-
-
-
-
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
-
-
-
-
-
-
-
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

